Welcome to STN International! Enter x:x

LOGINID:ssspta1617srh

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

```
 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2  Apr 08  "Ask CAS" for self-help around the clock
 NEWS  3  Apr 09  BEILSTEIN: Reload and Implementation of a New Subject Area
 NEWS  4  Apr 09  ZDB will be removed from STN
 NEWS  5  Apr 19  US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
 NEWS  6  Apr 22  Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
 NEWS  7  Apr 22  BIOSIS Gene Names now available in TOXCENTER
 NEWS  8  Apr 22  Federal Research in Progress (FEDRIP) now available
 NEWS  9  Jun 03  New e-mail delivery for search results now available
 NEWS 10  Jun 10  MEDLINE Reload
 NEWS 11  Jun 10  PCTFULL has been reloaded
 NEWS 12  Jul 02  FOREGE no longer contains STANDARDS file segment
 NEWS 13  Jul 22  USAN to be reloaded July 28, 2002;
                  saved answer sets no longer valid
 NEWS 14  Jul 29  Enhanced polymer searching in REGISTRY
 NEWS 15  Jul 30  NETFIRST to be removed from STN
 NEWS 16  Aug 08  CANCERLIT reload
 NEWS 17  Aug 08  PHARMAMarketLetter(PHARMAML) - new on STN
 NEWS 18  Aug 08  NTIS has been reloaded and enhanced
 NEWS 19  Aug 19  Aquatic Toxicity Information Retrieval (AQUIRE)
                  now available on STN
 NEWS 20  Aug 19  IFIPAT, IFICDB, and IFIUDB have been reloaded
 NEWS 21  Aug 19  The MEDLINE file segment of TOXCENTER has been reloaded
 NEWS 22  Aug 26  Sequence searching in REGISTRY enhanced
 NEWS 23  Sep 03  JAPIO has been reloaded and enhanced
 NEWS 24  Sep 16  Experimental properties added to the REGISTRY file
 NEWS 25  Sep 16  Indexing added to some pre-1967 records in CA/CAPLUS
 NEWS 26  Sep 16  CA Section Thesaurus available in CAPLUS and CA
 NEWS 27  Oct 01  CASREACT Enriched with Reactions from 1907 to 1985
 NEWS 28  Oct 21  EVENTLINE has been reloaded
 NEWS 29  Oct 24  BEILSTEIN adds new search fields
 NEWS 30  Oct 24  Nutraceuticals International (NUTRACEUT) now available on STN
 NEWS 31  Oct 25  MEDLINE SDI run of October 8, 2002

 NEWS EXPRESS  October 14 CURRENT WINDOWS VERSION IS V6.01,
               CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
               AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)
```

Enter NEWS followed by the item number or name to see news on that specific topic.

result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:03:28 ON 31 OCT 2002

=> fil reg
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:04:03 ON 31 OCT 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 29 OCT 2002 HIGHEST RN 467418-81-1
DICTIONARY FILE UPDATES: 29 OCT 2002 HIGHEST RN 467418-81-1

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP
PROPERTIES for more information. See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> s 162359-55-9/rn or 162359-55-9/crn
1 162359-55-9/RN
1 162359-55-9/CRN
L1 2 162359-55-9/RN OR 162359-55-9/CRN

=> fil medli capl biosis embase uspatful wpid
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.76	0.97

FILE 'MEDLINE' ENTERED AT 12:05:22 ON 31 OCT 2002

FILE 'CAPLUS' ENTERED AT 12:05:22 ON 31 OCT 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 12:05:22 ON 31 OCT 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 12:05:22 ON 31 OCT 2002
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'USPATFULL' ENTERED AT 12:05:22 ON 31 OCT 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 12:05:22 ON 31 OCT 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

```
=> s l1
'RN' IS NOT A VALID FIELD CODE
'CRN' IS NOT A VALID FIELD CODE
L2          632 L1

=> s FTY 720
L3          366 FTY 720

=> s l2 or l3
L4          643 L2 OR L3

=> s immunostimul? or immunoenhanc?
L5        48360 IMMUNOSTIMUL? OR IMMUNOENHANC?

=> s l4 and l5
L6            1 L4 AND L5

=> d

L6   ANSWER 1 OF 1  EMBASE  COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN   2002060333  EMBASE
TI   L-selectin-dependent lymphoid occupancy is required to induce
     alloantigen-specific tolerance.
AU   Bai Y.; Liu J.; Wang Y.; Honig S.; Qin L.; Boros P.; Bromberg J.S.
CS   Dr. J.S. Bromberg, Mount Sinai School of Medicine, Box 1104, One Gustave
     L. Levy Place, New York, NY 10029-6574, United States.
     jon.bromberg@mountsinai.org
SO   Journal of Immunology, (15 Feb 2002) 168/4 (1579-1589).
     Refs: 48
     ISSN: 0022-1767  CODEN: JOIMA3
CY   United States
DT   Journal; Article
FS   018     Cardiovascular Diseases and Cardiovascular Surgery
     026     Immunology, Serology and Transplantation
     030     Pharmacology
     037     Drug Literature Index
LA   English
SL   English


=> s viral or antiviral or antiviru? or viru?
   3 FILES SEARCHED...
L7      2026272 VIRAL OR ANTIVIRAL OR ANTIVIRU? OR VIRU?

=> s l7 and l4
L8            27 L7 AND L4

=> dup rem l8
PROCESSING COMPLETED FOR L8
L9            21 DUP REM L8 (6 DUPLICATES REMOVED)

=> d ibib abs 16-21

L9   ANSWER 16 OF 21     MEDLINE                          DUPLICATE 3
ACCESSION NUMBER:   2000281664     MEDLINE
DOCUMENT NUMBER:    20281664   PubMed ID: 10820254
TITLE:              FTY720 immunosuppression impairs effector T cell peripheral
                    homing without affecting induction, expansion, and memory.
AUTHOR:             Pinschewer D D; Ochsenbein A F; Odermatt B; Brinkmann V;
                    Hengartner H; Zinkernagel R M
CORPORATE SOURCE:   Institute of Experimental Immunology and Laboratory for
```

Special Techniques, Department of Pathology, University Hospital, Zurich, Switzerland.
SOURCE: JOURNAL OF IMMUNOLOGY, (2000 Jun 1) 164 (11) 5761-70. Journal code: 2985117R. ISSN: 0022-1767.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
ENTRY MONTH: 200006
ENTRY DATE: Entered STN: 20000629
Last Updated on STN: 20000629
Entered Medline: 20000621

AB FTY720 (2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol hydrochloride) prolongs survival of solid organ allografts in animal models. Mechanisms of FTY720 immunomodulation were studied in mice infected with lymphocytic choriomeningitis **virus** (LCMV) to assess T cell responses or with vesicular stomatitis **virus** to evaluate Ab responses. Oral FTY720 (0.3 mg/kg/day) did not affect LCMV replication and specific CTL and B cells were induced and expanded normally. Moreover, the anti-**viral** humoral immune responses were normal. However, FTY720 treatment showed first a shift of overall distribution of CTL from the spleen to peripheral lymph nodes and lymphocytopenia was observed. This effect was reversible within 7-21 days. Together with unimpaired T and B cell memory after FTY720 treatment, this finding rendered enhancement of lymphocyte apoptosis by FTY720 in vivo unlikely. Secondly, the delayed-type hypersensitivity reaction to a **viral** MHC class I-presented peptide was markedly reduced by FTY720. These results were supported by impaired circulation of LCMV specific TCR transgenic effector lymphocytes in the peripheral blood and reduced numbers of tissue infiltrating CTL in response to delayed-type hypersensitivity reaction. Thirdly, in a CD8+ T cell-mediated diabetes model in a transgenic mouse expressing the LCMV glycoprotein in the islets of the pancreas, FTY720 delayed or prevented disease by reducing islet-infiltrating CTL. Thus, FTY720 effectively reduced recirculation of CD8+ effector T cells and their recruitment to peripheral lesions without affecting the induction and expansion of immune responses in secondary lymphoid organs. These properties may offer the potential to treat ongoing organ-specific T cell-mediated immunopathologic disease.

L9 ANSWER 17 OF 21 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:896183 CAPLUS
DOCUMENT NUMBER: 135:55693
TITLE: Perioperative administration of FTY720 and CTLA4IG in rat heart transplantation
AUTHOR(S): Ohba, M.; Li, X.-K.; Kita, Y.; Tamura, A.; Enosawa, S.; Sasakuri, S.; Ogoshi, S.; Amemiya, H.; Suzuki, S.
CORPORATE SOURCE: Department of Experimental Surgery and Bioengineering, National Children's Medical Research Center, Tokyo, Japan
SOURCE: Transplantation Proceedings (2000), 32(7), 2024-2025 CODEN: TRPPA8; ISSN: 0041-1345
PUBLISHER: Elsevier Science Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A study was conducted to examine the in vitro proliferation activity of lymphocytes from recipients transfected with adenovirus vectors contg. CTLA4Ig-gene (AdCTLA4Ig) and FTY720 administered in a rat model of allogeneic heart transplantation. The administration of FTY720 or AdCTLA4Ig resulted in significant prolongation of allograft survival. The combination therapy with FTY720 and AdCTLA4Ig caused further prolongation effects on graft survival time. The in vitro proliferation activity of lymphocytes to donor cells were completely inhibited early after grafting

in both FTY720-treated recipients and AdCTLA4Ig-treated ones. FTY720-treated recipients showed a marked suppression in lymphocyte response 14 days after grafting, whereas the lymphocytes from AdCTLA4Ig-treated recipients recovered the response despite absence of a rejection episode. In addn., a remarkable inhibition of mixed lymphocyte reaction was obsd. in the lymphocytes from recipients with combination therapy.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 18 OF 21 USPATFULL

ACCESSION NUMBER: 1999:166606 USPATFULL

TITLE: Compositions and methods of using compositions with accelerated lymphocyte homing immunosuppressive properties

INVENTOR(S): Chiba, Kenji, Fukuoka, Japan
Adachi, Kunitomo, Fukuoka, Japan

PATENT ASSIGNEE(S): Yoshitomi Pharmaceutical Industries, Ltd., Osaka, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6004565		19991221	
APPLICATION INFO.:	US 1997-933738		19970923	(8)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1997-237273	19970902

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Saunders, David
ASSISTANT EXAMINER: Tung, Mary Beth
LEGAL REPRESENTATIVE: Evenson, McKeown Edwards & Lenahan P.L.L.C.
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 26 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 1536
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The methods and compositions of the invention and the compounds used in the invention involve a novel immunosuppression mechanism, accelerated lymphocyte homing immunosuppression (ALH-immunosuppression). For example, the compound FTY720 specifically directs lymphocytes to the peripheral lymph nodes, mesenteric lymph nodes, and Peyer's patches. By reversibly sequestering lymphocytes in these tissues, the compounds can inhibit an immune response in a mammal. Understanding these mechanisms provides a novel immunosuppression therapy that can synergistically interact with other immunosuppressive compounds. Screening methods for identifying similar ALH-immunosuppression compounds are also described. The invention allows better treatments and therapies wherever an immunosuppression regimen is desired.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 19 OF 21 USPATFULL

ACCESSION NUMBER: 1999:106496 USPATFULL

TITLE: Benzene compound and pharmaceutical use thereof

INVENTOR(S): Fujita, Tetsuro, Muko, Japan
Adachi, Kunitomo, Chikujo-gun, Japan
Kohara, Toshiyuki, Iruma, Japan
Kiuchi, Masatoshi, Iruma, Japan
Chiba, Kenji, Chikujo-gun, Japan
Teshima, Koji, Iruma, Japan

	Mishina, Tadashi, Chikujo-gun, Japan
PATENT ASSIGNEE(S):	Yoshitomi Pharmaceutical Industries, Ltd., Osaka, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5948820		19990907
APPLICATION INFO.:	US 1997-801390		19970220 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 1995-JP1654, filed on 22 Aug 1995		

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1994-196888	19940822
	JP 1995-82934	19950407
	JP 1995-172543	19950707

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Raymond, Richard L.
LEGAL REPRESENTATIVE:	Evenson, McKeown Edwards & Lenahan P.L.L.C.
NUMBER OF CLAIMS:	37
EXEMPLARY CLAIM:	1
LINE COUNT:	10327

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A benzene compound of the formula ##STR1## wherein each symbol is as defined in the specification; an optically active isomer or salt thereof, a medicinal composition containing the same, and an immunosuppressant containing the same as the active ingredient.

The compound, optically active isomer or salt has an excellent immunosuppressive effect and is useful as an inhibitor for the rejection reaction occurring in organ or bone marrow transplantation, and as a preventive or remedy for articular rheumatism, atopic eczema (dermatitis), Beh.cedilla.et's disease, uveal disease, systemic lupus erythematosus, Sjogren's syndrome, multiple sclerosis, myasthenia gravis, type I diabetes, endocrine ophthalmopathy, primary biliary, cirrhosis, Crohn's disease, glomerulonephritis, sarcoidosis, psoriasis, pemphigus, aplastic anemia, idiopathic thrombocytopenic purpura, allergy, polyarteritis nodosa, progressive systemic sclerosis, mixed connective-tissue disease, aortitis syndrome, polymyositis, dermatomyositis, Wegener's granuloma, ulcerative colitis, active chronic hepatitis, autoimmune hemolytic anemia, Evans' syndrome, bronchial asthma and pollinosis. It is useful also as an antifungal agent and hair growth stimulant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 20 OF 21 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER:	2000:527310 BIOSIS
DOCUMENT NUMBER:	PREV200000527310
TITLE:	Recurrent renal allograft rejection: Therapeutic options.
AUTHOR(S):	Hauser, Ingeborg A. (1)
CORPORATE SOURCE:	(1) Funktionsbereich Nephrologie, Johann Wolfgang Goethe-Universitaet, Frankfurt/Main Germany
SOURCE:	Kidney & Blood Pressure Research, (1999) Vol. 22, No. 4-6, pp. 259-263. print. Meeting Info.: Joint Scientific Meeting of the Society for Nephrology and the German Working Group for Clinical Nephrology Freiburg, Germany September 18-21, 1999 ISSN: 1420-4096.
DOCUMENT TYPE:	Conference
LANGUAGE:	English

SUMMARY LANGUAGE: English

L9 ANSWER 21 OF 21 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 1999049708 EMBASE
TITLE: Immunology - Tenth International Congress.
AUTHOR: Vohora S.B.; Raisuddin S.
CORPORATE SOURCE: S.B. Vohora, Dept. of Med. Elementol./Toxicology, Jamia Hamdard (Hamdard University), New Delhi 110 062, India. root@hamduni.ren.nic.in
SOURCE: IDrugs, (1999) 2/1 (22-25).
ISSN: 1369-7056 CODEN: IDRUFN
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; Conference Article
FILE SEGMENT: 026 Immunology, Serology and Transplantation
030 Pharmacology
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English
AB This report provides selective coverage of this meeting. Over 2000 participants (including some Nobel laureates) from 67 countries attended. Among these was a significant number from Eastern European countries. This report focuses primarily on DNA vaccines and conventional vaccine development, as well as drug development. It also covers some of the plenary lectures that were delivered by immunology luminaries. The overall focus of the meeting centered on developments in the areas of vaccines, HIV and immune mechanisms. A significant number of presentations concentrated on tumor immunology and immunotherapy. Immunomodulation was another area of major discussion. With such a large, well-attended meeting, it is difficult to provide coverage for each of the speakers in a particular section, and the omissions are unintentional.

=> d kwic 20-21

L9 ANSWER 20 OF 21 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
IT . . .
& Systems of Organisms
renal artery: circulatory system, excretory system, structural changes
IT Diseases
CMV infection [cytomegalovirus infection]: concomitant disease, **viral** disease; acute rejection: immune system disease, pathogenesis, urologic disease; chronic rejection: immune system disease, pathogenesis, urologic disease; late renal allograft loss: immune system disease, prevention, urologic disease; polyoma **virus** infection: concomitant disease, **viral** disease; recurrent renal allograft rejection: immune system disease, pathogenesis, treatment options, treatment outcomes, urologic disease; renal allograft rejection: classifications, diagnosis,. . .
RN 104987-11-3 (FK506)
104987-11-3 (TACROLIMUS)
162359-56-0 (FTY720)
59865-13-3 (CYCLOSPORINE A)
216973-42-1 (CSA)
1247-42-3 (METHYLPREDNISONE)
128794-94-5 (MYCOPHENOLATE MOFETIL)
53123-88-9 (RAPAMYCIN)
53123-88-9 (SIROLIMUS)

L9 ANSWER 21 OF 21 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
CT Medical Descriptors:
*immunology
*drug research

human immunodeficiency virus 1
tumor immunology
immunomodulation
vaccination
drug manufacture
delayed hypersensitivity
drug design
immune response
cross reaction
cytokine production
human
clinical trial
meta analysis
multicenter study
human tissue
human cell
conference paper
*DNA vaccine: CT, clinical. . .

RN (2 amino 2 [2 (4 octylphenyl)ethyl] 1,3 propanediol) **162359-56-0** ; (gonadorelin) 33515-09-2, 9034-40-6; (interleukin 2) 85898-30-2; (milodistim) 137463-76-4; (lymphotactin) 156561-05-6; (thalidomide derivative) 31804-66-7

CN **(1) Fty 720**; (2) Cc 3052

=> log h

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	50.45	51.42

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.62	-0.62

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 12:19:26 ON 31 OCT 2002